Mutations in the PP2A regulatory subunit B family genes PPP2R5B, PPP2R5C and PPP2R5D cause human overgrowth by Loveday, Chey et al.
OR I G INA L ART I C L E
Mutations in the PP2A regulatory subunit B family genes
PPP2R5B, PPP2R5C and PPP2R5D cause human
overgrowth
Chey Loveday1,†, Katrina Tatton-Brown1,3,4,†, Matthew Clarke1,
Isaac Westwood2, Anthony Renwick1, Emma Ramsay1, Andrea Nemeth5,
Jennifer Campbell6, Shelagh Joss7,8, McKinlay Gardner9, Anna Zachariou1,
Anna Elliott1, Elise Ruark1, Rob van Montfort2, The Childhood Overgrowth
Collaboration1 and Nazneen Rahman1,4,*
1Division of Genetics and Epidemiology, 2Cancer Research UK Cancer Therapeutics Unit and Division of
Structural Biology, Institute of Cancer Research, London, UK, 3Medical Genetics Unit, St George’s University of
London, London, UK, 4Cancer Genetics Unit, Royal Marsden Hospital, London, UK, 5Department of Clinical
Genetics, Churchill Hospital, Oxford, UK, 6Institute of Genetic Medicine, International Centre for Life, Newcastle
University, Newcastle upon Tyne, UK, 7West of Scotland Genetic Services, Southern General Hospital, Scotland,
UK, 8Yorkshire Regional Clinical Genetics Service, Chapel Allerton Hospital, Leeds, UK and 9Genetic Health
Service New Zealand, Wellington Hospital, Wellington, NZ
*To whom correspondence should be addressed at: Division of Genetics and Epidemiology, Institute of Cancer Research, 15 Cotswold Road, Sutton,
London SM2 5NG, UK. Tel: +44 20 87224145; Fax: +44 20 87224359; Email: rahmanlab@icr.ac.uk
Abstract
Overgrowth syndromes comprise a group of heterogeneous disorders characterised by excessive growth parameters, often
in association with intellectual disability. To identify new causes of human overgrowth, we have been undertaking trio-based
exome sequencing studies in overgrowth patients and their unaffected parents. Prioritisation of functionally relevant genes
with multiple unique de novomutations revealed four mutations in protein phosphatase 2A (PP2A) regulatory subunit B family
genes protein phosphatase 2, regulatory Subunit B’, beta (PPP2R5B); protein phosphatase 2, regulatory Subunit B’, gamma (PPP2R5C); and
protein phosphatase 2, regulatory Subunit B’, delta (PPP2R5D). This observation in 3 related genes in 111 individuals with a similar
phenotype is greatly in excess of the expected number, as determined from gene-specific de novomutation rates
(P = 1.43 × 10−10). Analysis of exome-sequencing data from a follow-up series of overgrowth probands identified a further
pathogenic mutation, bringing the total number of affected individuals to 5. Heterozygotes shared similar phenotypic features
including increasedheight, increasedhead circumference and intellectual disability. Themutations clusteredwithin a region of
nine amino acid residues in the aligned protein sequences (P = 1.6 × 10−5). Wemapped the mutations onto the crystal structure
of the PP2A holoenzyme complex to predict their molecular and functional consequences. These studies suggest that the
mutations may affect substrate binding, thus perturbing the ability of PP2A to dephosphorylate particular protein substrates.
†These authors contributed equally to the work.
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PP2A is amajor negative regulator of v-aktmurine thymomaviral oncogenehomolog 1 (AKT). Thus, our data further expand the
list of genes encoding components of the phosphatidylinositol-4,5-bisphosphate 3-kinase (PI3K)/AKT signalling cascade that
are disrupted in human overgrowth conditions.
Introduction
Overgrowth syndromes are a heterogeneous group of disorders
characterised by excess prenatal and postnatal growth compared
with the age-matched peer group. While for the majority of
individuals the molecular aetiology of their condition remains
unknown, several overgrowth-associated genes have been iden-
tified in recent years, many of which encode components of
the phosphatidylinositol-4,5-bisphosphate 3-kinase (PI3K)/v-akt
murine thymomaviral oncogene homolog 1 (AKT) growth regula-
tory cascade (Supplementary Material, Fig. S1) (1).
De novo genemutations are a cause of several overgrowth con-
ditions, and their detection by exome sequencing has proved a
successful strategy for the identification of novel genetic causes
of overgrowth syndromes (2,3). To further leverage this strategy,
we are undertaking trio-based exome sequencing in individuals
with a range of overgrowth phenotypes and their unaffected par-
ents. Herein, we report five affected individuals from unrelated
families with de novo mutations in the protein phosphatase 2A
(PP2A) regulatory subunit B family genes protein phosphatase 2,
regulatory Subunit B’, beta (PPP2R5B), protein phosphatase 2, regula-
tory Subunit B’, gamma (PPP2R5C) and protein phosphatase 2, regula-
tory Subunit B’, delta (PPP2R5D).
Results
We have completed exome sequencing in 111 trios (Supplemen-
tary Material, Table S1) using Illumina exome enrichment kits
and sequencers, performing alignment and variant calling with
our in-house pipeline, identifying a total of 94 putative de novo
coding variants. We first considered genes with more than one
de novomutation, amongst which was PPP2R5D (RefSeq accession
number NM_006245), in which closely located de novo non-syn-
onymous mutations, c.592G>A (p.Glu198Lys) and c.598G>A (p.
Glu200Lys), were identified in two individuals (Fig. 1, Table 1).
PPP2R5D encodes B56δ, one of the PP2A regulatory B subunits.
PP2A-B56 is a key cellular serine-threonine phosphatase with
roles in multiple pathways including negative regulation of the
PI3K/AKT growth regulatory cascade [reviewed in (4)]. Given the
established role of this pathway in growth regulation and over-
growth phenotypes, this gene was of immediate interest.
PPP2R5D is one of five genes encoding PP2A-B56 subunit pro-
teins; the others are protein phosphatase 2, regulatory Subunit B’,
alpha (PPP2R5A); PPP2R5B, PPP2R5C and protein phosphatase 2, regu-
latory Subunit B’, epsilon (PPP2R5E), which encode B56α, B56β, B56γ
and B56ε, respectively. Given our initial findings, we reviewed the
exome data at the other PP2A-B56 subunit genes, which revealed
de novomutations in PPP2R5B (c.482C>T [p.Ser161Leu]; RefSeq ac-
cession number NM_006244) and PPP2R5C (c.468_470delAAC [p.
Thr157del]; RefSeq accession numberNM_001161725) in a further
two individuals. Notably, these mutations were at similarly posi-
tioned residues to those identified in PPP2R5D (Fig. 1A). We con-
firmed all four mutations were present in the relevant proband
and absent from their parents by Sanger sequencing (Supple-
mentary Material, Fig. S2). Additionally, none of the mutations
were present in 1000 population controls (the ICR1000 series) in
which exome sequencing had been performed using the same la-
boratory and analytical pipelines (4/111 versus 0/1000; P = 0.0001).
Furthermore, the identification of 4 de novomutations in 3 closely
related genes in 111 individuals with a similar phenotype is
greatly in excess of the expected number, as determined from
gene-specific de novo mutation rates (P = 1.43 × 10−10; see Materi-
als and Methods for test description).
We next analysed exome data at PPP2R5B, PPP2R5C and
PPP2R5D in a separate series of 152 individuals with overgrowth
phenotypes for whom parental DNA is not available (the single-
ton series; Supplementary Material, Table S1). We identified one
individual with PPP2R5D p.Glu200Lys, which is likely causative of
their phenotype as the identicalmutation had occurred de novo in
one of the trio series (Table 1). Of note, none of the five pathogenic
mutations showed any evidence of mosaicism, either by themu-
tation read percentages in the next generation sequencing data
or the Sanger sequencing traces (Supplementary Material, Fig.
S2). Three other rare non-synonymous variants were detected,
but in the absence of additional evidence, a causal relationship
with overgrowth cannot be inferred for these variants (Supple-
mentary Material, Table S2).
We undertook structural analysis to gain insights into the pos-
sible impact of themutationswe identified in overgrowth cases on
PP2A-B56 function. Themutations were all locatedwithin a highly
conserved region of the PP2A-B56 subunits; indeed, they clustered
within a nine amino acid region in intra-repeat loop 2 (P = 1.6 ×
10−5; Fig. 1A; Fig. 1B). PP2A exists as a heterotrimeric holoenzyme
comprising a catalytic ‘C’, structural ‘A’ and a regulatory ‘B’ sub-
unit. The crystallised structure of the B56 core domain comprises
18 alpha helices organised into 8 huntingtin, elongation factor 3
(EF3), protein phosphatase 2A (PP2A) and the yeast kinase TOR1
(HEAT)-like repeats that form an exposed concave surface residing
adjacent to the catalytic site of the PP2A catalytic subunit (Fig. 1B).
This concave surface is enriched with negatively charged amino
acids and forms, along with the C subunit, a cleft for substrate
binding. All identified mutations map to residues forming intra-
repeat loop 2, which is also termed the substrate specificity
loop and is located within the exposed substrate-binding cleft
(Fig. 1B). The substrate specificity loop is believed to regulate
both substrate recognition and orientation, such that the amino
acid targeted for dephosphorylation is placed near the active site
of the catalytic subunit (5). Thus, it is plausible that themutations
reported here cause impaired substrate-specific phosphatase ac-
tivity owing to perturbed substrate recognition and/or positioning.
Functional studies are required to confirm this hypothesis and to
identify the targeted substrate protein(s).
We next evaluated the phenotypic data for individuals with
pathogenic PP2A-B56 subunit mutations (Table 1, Supplemen-
tary Material). The facial features were not distinctive (Fig. 1C).
The median head circumference was 3.6 standard deviations
above themean. Two of the three individuals with PPP2R5Dmu-
tations were also tall with heights greater than two standard de-
viations above the mean and thus had global overgrowth. In
contrast, the individual with a PPP2R5B mutation had a normal
head circumference but was very tall with a height three stand-
ard deviations above the mean (Table 1). All five individuals
were said to have an intellectual disability by the referring clin-
ician. These data indicate that overgrowth and intellectual dis-
ability are key clinical features of PP2A-B56 subunit mutations.
However, it should be noted that increased height and/or head
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circumference is an eligibility criterion for the Childhood Over-
growth (COG) study together with at least one other clinical fea-
ture, which is often intellectual disability. Therefore, the full
phenotypic spectrum of PP2A-B56 subunit mutations may
be broader than demonstrated here. Moreover, the absence
of distinctive clinical features associated with PP2A-B56 muta-
tions further underscores the high genetic heterogeneity of
overgrowth conditions. It is interesting that contemporaneously
and independently of our study the Deciphering Developmental
Disorders study identified four de novo PPP2R5D mutations
amongst 1133 individuals with developmental disorders (6).
Three had c.592G>A (p.Glu198Lys), the mutation we also identi-
fied and the other had c.602C>G (p.Pro201Arg), which is also
located in the substrate specificity loop. Variable phenotypic
features were observed, but one individual was noted to have
increased head circumference (Supplementary Material,
Table S3). To our knowledge, de novo mutations in PPP2R5B and
PPP2R5C have not been reported.
Figure 1. PP2A-B56mutations in humanovergrowth. (A) Protein schematic showing the distribution of PP2A-B56 subunitmutations in individualswith overgrowth (above,
red lollipops) versus variants identified in the ICR1000 control series (below, grey lollipops). The shared core B56 domain is shown in orange and the intra-repeat loop 2
region in blue. (B) PP2A-B56 subunitmutationsmapped onto the PP2A-B56γ complex. PP2A-B56γ is shown in orange, the catalytic subunit is in light brown and the scaffold
subunit is in yellow. The intra-repeat loop 2 of PP2A-B56γ is highlighted in blue. The residues corresponding to the mutations identified are shown as red spheres. Inset:
interaction of PP2A-B56γ p.Glu153with the PP2A-Cα subunit. The glutamate side chain forms an ion pair interaction andwater-mediatedH-bonds to Arg residues from the
catalytic subunit. (C) Facial characteristics of individuals with PP2A-B56 subunit mutations. Growth parameters and clinical features are described in Table 1. Specific
consent to publish facial photographs was obtained for all individuals.
Table 1. PP2A-B56 mutations and associated phenotypes
Case ID Gene Mutation Inheritance Age/
years
Ht/ HC/ Intellectual
disability
Other clinical features
Nucleotide Amino acid s.d. s.d.
COG1744 PPP2R5D c.592G>A p.Glu198Lys de novo 0.3 2.3 3.6 Yes Hypospadias
COG1674 PPP2R5D c.598G>A p.Glu200Lys de novo 1.7 −1.4 3.8 Yes
COG0328 PPP2R5D c.598G>A p.Glu200Lys unknown 14 2 3.8 Yes Parkinsonism
COG0681 PPP2R5C c.468_470delAAC p.Thr157del de novo 9.3 1.6 3.3 Yes Facial asymmetry,
conductive hearing loss
COG0955 PPP2R5B c.482C>T p.Ser161Leu de novo 17.5 3 0.3 Yes Swelling of PIPJ
Mutation positions in PPP2R5B, PPP2R5C and PPP2R5D correspond to RefSeq sequences NM_006244, NM_001161725 and NM_006245, respectively.
Ht/s.d., height/standard deviation; HC/s.d., head circumference/standard deviation; PIPJ, proximal interphalangeal joint.
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Discussion
We have identified heterozygous missense mutations in
PP2A regulatory subunit B family genes PPP2R5B, PPP2R5C and
PPP2R5D in individuals with overgrowth and intellectual disabil-
ity. Structural analysis indicates that the mutations affect the
PP2A-B56 substrate specificity loop, plausibly altering the ability
of PP2A-B56 to dephosphorylate target substrates.
PP2A has been implicated in a multitude of signalling cas-
cades that control cell proliferation, division, differentiation,
apoptosis, metabolism, adhesion and migration and is thought
to modulate the activity of over 30 different kinases [reviewed
in (4)]. This diversity in PP2A function is conferred in part by
the range of different regulatory B subunits, with each B subunit
family directing the PP2A complex to distinct and overlapping
targets. Multiple lines of evidence indicate that the PP2A-B56
holoenzyme has particular specificity for AKT, a major compo-
nent of the PI3K/AKT growth regulatory cascade. More specifical-
ly, PP2A-B56 has been shown to inhibit AKT activity in specific
subcellular compartments through the direct dephosphorylation
of AKT Thr308 and Ser473 (7,8). In its phosphorylated state, AKT
promotes cellular growth and proliferation. Thus, in normal cells,
PP2A-B56 is a negative regulator of the PI3K/AKT growth regula-
tory cascade.
It is plausible that the mutations described here disrupt the
ability of PP2A-B56 to dephosphorylate AKT, thus disrupting its
ability to negatively regulate the PI3K/AKT growth regulatory
cascade. Indeed, multiple genes encoding components of the
PI3K/AKT growth regulatory cascade have been causally impli-
cated in human growth disorders (Supplementary Material,
Fig. S1). Foremost amongst these is phosphatase and tensin holog
(PTEN), inactivatingmutations ofwhich cause increasedhead cir-
cumference, a core feature of all the PTEN-associated syndromes,
such as Bannayan Riley Ruvalcaba syndrome (MIM 153480) and
Cowden syndrome (MIM 158350) (9). In addition, somatic activat-
ing phosphatidylinosiltol-4,5-bisphosphate 3-kinase, catalytic subunit
alpha (PIK3CA) mutations and germline activating phosphoinosi-
tide-3-kinase, regulatory subunit 2 (beta) (PIK3R2) mutations (both
encoding PI3K regulatory subunits) cause conditions characterized
by increasedheadcircumference;megalencephaly-capillarymalfor-
mation (MCAP [MIM 602501]) and megalencephaly-polymicrogyria-
polydactyly-hydrocephalus (MPPH [MIM 603387]) syndromes,
respectively (10). Activating germline and somatic AKT3mutations
has also been described in a small number of individuals with
atypical MPPH and hemimegalencephaly (MPPH2 [MIM 615937])
(10). Finally, activating somatic mutations in AKT1 cause Proteus
syndrome (MIM 176920), a highly variable disorder of asymmetric
overgrowth, tissue hyperplasia affecting multiple organs and in-
creased tumour risk (Supplementary Material, Fig. S1) (11). These
findings, in conjunction with the data presented here, suggest that
further components of the PI3K/AKT pathwaymay also be involved
in human growth disorders.
Materials and Methods
Case series
We recruited individuals with overgrowth through the COG
study. The research was approved by the London Multicentre
Ethics Committee (reference MREC/01/2/44), and informed con-
sent was obtained from all participants and/or families. We ex-
tracted DNA from peripheral blood. We obtained phenotypic
information through a standardized questionnaire. A summary
of the overgrowth phenotypes used in this study is given in
Supplementary Material, Table S1. A full list of collaborators is
given in the Supplementary Material.
ICR1000 control series
We used lymphocyte DNA from 1000 population-based controls
obtained from the 1958 Birth Cohort Collection (http://www2.le.
ac.uk/projects/birthcohort), a continuing follow-up study of indi-
viduals born in the UK in 1 week in 1958. The ICR1000 series [Ac-
cession number: EGAS00001000971] is accessible from the
European Genome-phenome Archive (https://www.ebi.ac.uk/
ega/datasets/EGAD00001001021).
Exome sequencing
We performed target enrichment using either the TruSeq Exome
Enrichment Kit or the Nextera Exome Enrichment Kit, targeting
62 Mb and 37 Mb of the human genome, respectively. Captured
DNA libraries were PCR amplified using the supplied paired-end
PCR primers. Sequencing was performed on either an Illumina
HiSeq 2000 or 2500, generating 2 × 101-bp and 2 × 100-bp reads,
respectively.
Exome variant calling and de novo mutation detection
We used Stampy (version 1.0.14) to map sequencing reads to the
human reference genome (hg19). Duplicate reads were flagged
using Picard version 1.60. We used Platypus version 0.1.5 to per-
formvariant callingwhereas annotationwas performed byCAVA,
a variant annotation tool written in Python that follows Human
Genome Variation Society nomenclature and ensures consistent
annotation of indels (http://www.well.ox.ac.uk/cava).
Prior to the de novo analyses, we checked the pairwise related-
ness of all individuals in each trio, confirming biological parent-
age in all. For the de novo analyses, we used a custom script
written in Perl to remove variants that were either present or
not sufficiently covered in the corresponding parental samples
or were supported by less than three reads. We then prioritised
genes for follow-up based on number of de novo mutations and
candidacy. Following the identification of de novo mutations in
PPP2R5B, PPP2R5C and PPP2R5D in the trio series, we reviewed
all high-quality variant calls in these genes in the singleton series
and the ICR1000 control series.
Sanger sequencing
We used Sanger sequencing of M13 tagged-PCR products from
genomic DNA to validate all variants identified in probands by
exome sequencing and to confirm the absence in parental sam-
ples as appropriate. Primer hybridisation sequences used for PCR
are given in Supplementary Material, Table S4. PCRs were per-
formed using the QiagenMultiplex PCR Kit according to theman-
ufacturer’s instructions. PCR products were sequenced usingM13
sequencing primers, the BigDye Terminator Cycle Sequencing Kit
and an ABI 3730 Genetic Analyser (Applied Biosystems). Se-
quences were analysed using Mutation Surveyor software v3.20
(SoftGenetics) and verified by manual inspection.
Genbank accession numbers
Mutation positions were assigned according to the following
human mRNA reference sequences: NM_006244 (PPP2R5B),
NM_001161725 (PPP2R5C) and NM_006245 (PPP2R5D).
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Statistical analyses
We compared mutation frequencies using a two-sided Fisher’s
Exact test. The significance of the observed pattern of multiple
de novo mutations across the genes PPP2R5B, PPP2R5C and
PPP2R5Dwas assessed using the method described in (8). Briefly,
we calculated the number of expected de novo mutations across
the three genes by summing the gene-specific mutation rates
[as defined by Samocha et al. (12)] by the number of transmissions
(i.e. twice the number of probands). This value was then used as
the mean of a Poisson distribution from which the probability of
getting the observed number of mutations (i.e. four) within these
genes was taken.
We undertook clustering analysis to assess the significance of
the four de novo mutations occurring within a region of nine
amino acid residues in the aligned protein sequences. Using
onemillion permutations, we randomly placedmutationswithin
each of the three genes according to the number observed, calcu-
lating the distance in bases between the two furthest mutations.
The proportion of simulated mutations occurring within nine
amino acids or fewer was compared with the observed number
to determine the P-value.
Structural analyses
PP2A-B56 variants were mapped to their corresponding residues
in the crystal structure of the PP2A holoenzyme (Aα-B56γ-Cα) in
complex with Shugoshin-like 1 (Sgo1) (Protein Data Bank acces-
sion code 3FGA) (13). Images were generated with CCP4MG (14).
The shugoshin Sgo1 homodimer and inhibitor toxin microcystin
peptide have been omitted for clarity.
Supplementary Materials
Supplementary Material is available at HMG online.
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